2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3548 Defining the clinical, genomic, and therapeutic landscape of non-IgM lymphoplasmacytic lymphoma

Alberto Guijosa, MD, Grace M Ferri, MD2, Nicolò Danesin, MD3, Nickolas Tsakmaklis4, Joshua Gustine, MD, MPH5, Margaret Kobs, NP6, Amanda Kofides, MSc7, Maria Luisa Guerrera, MD8, Camille Edwards, MD9, Tarek Mouhieddine, MD10, Zachary R Hunter, PhD11, Steven Treon, MD, PhD12, Shayna Sarosiek, MD13, Gottfried von Keudell, MD14, Andrew Branagan, MD, PhD15, Jorge J Castillo, MD16
1 Brigham and Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, University of Padova, Padova, Italy
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
15 Massachusetts General Hospital, Boston, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Patients with non-IgM lymphoplasmacytic lymphoma (LPL) have been systematically excluded from Waldenström macroglobulinemia (WM) clinical trials, leaving its biology and optimal treatment poorly defined. The IWWM-12 consensus panel recommended managing non-IgM LPL following WM guidelines, based mostly on expert opinion and limited data. We conducted the largest multicenter study to date to characterize non-IgM LPL’s clinicopathologic and genomic features, compare first-line treatment outcomes, and benchmark Bruton tyrosine kinase inhibitor (BTKi) efficacy against WM.

Methods: We identified consecutive patients with bone marrow-confirmed non-IgM LPL evaluated at Dana-Farber Cancer Institute, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center between 2005 and 2025. MYD88, CXCR4, and TP53 were assessed by allele-specific PCR (AS-PCR), Sanger sequencing, or next-generation sequencing (NGS), with a 52-patient subset undergoing uniform targeted NGS. Cytogenetics used G-banded karyotyping. Responses followed IWWM-12 criteria. BTKi recipients were matched 1:3 by exact matching (agent, line, age, treatment year) to BTKi-treated WM patients. Time-to-event outcomes were estimated by Kaplan-Meier and compared by log-rank test; multivariable logistic and Cox models were adjusted for sex and age.

Results: Among 139 patients (IgG 97 [70%], IgA 27 [19%], non-secretory 13 [9%], light chain-only 2 [1%]), median age was 64 years and median follow-up 5.5 years. MYD88 was mutated in 100/113 tested patients (89%) overall but in 57/60 (95%) tested by guideline-recommended AS-PCR. CXCR4 was mutated in 21/68 (31%) and TP53 in 4/68 (6%), with del(17p) in 1/61 (2%). del(6q) was the most common cytogenetic abnormality (10/105 [10%]). In the 52-patient NGS subset, MYD88 (65%) and CXCR4 (23%) were the most frequent mutations, with DNMT3A (15%) and TET2 (10%) consistent with clonal hematopoiesis.

Compared with IgG LPL, IgA LPL had higher rates of hyperviscosity (15% vs 1%; p=0.001), Bing-Neel syndrome (15% vs 2%; p=0.006), pleural effusions (15% vs 2%; p=0.006), and histologic transformation (7% vs 1%; p=0.056). Five-year overall survival (OS; 86% vs 93%; p=0.054) and survival after first-line treatment initiation (SAFTI; 82% vs 91%; p=0.080) were lower in IgA LPL, which remained independently associated with inferior SAFTI (HR 2.88; 95% CI 1.03-8.02; p=0.044) after adjusting for age and sex.

Of 105 treated patients (76%), median time from diagnosis to treatment was 10.7 months and median follow-up from first-line initiation was 5.2 years. Overall response rate was 55/79 (70%), with major response in 42/79 (53%); median PFS, TTNT, and SAFTI were 4.7, 5.1, and 18.9 years. Among the four most common first-line regimens, BTKi (n=24) and bendamustine-rituximab (BR; n=26) produced the best outcomes compared with rituximab monotherapy (R; n=33) and cyclophosphamide-based regimens (Cy; n=9). VGPR or better was achieved in 45%, 60%, 19%, and 38%, respectively (p=0.061). Three-year PFS was 92%, 69%, 39%, and 56% (p<0.001), and 3-year TTNT was 88%, 86%, 45%, and 56%, respectively (p<0.001). In multivariable analysis, BTKi and BR independently improved PFS and TTNT versus R (p≤0.006). Three-year SAFTI did not differ across regimens (p=0.322).

Among 49 BTKi recipients (24 frontline, 25 relapsed/refractory), VGPR or better was 17/38 (45%), with 3-year PFS, TTNT, and OS of 91%, 76%, and 95%. In the 1:3 matched analysis (41 non-IgM LPL vs 123 WM), VGPR or better (47% vs 33%; p=0.155), 3-year PFS (91% vs 82%; p=0.165), TTNT (78% vs 66%; p=0.429), and OS (97% vs 95%; p=0.509) were comparable.

Conclusions: In the largest cohort reported to date, non-IgM LPL closely resembles WM in its genomic drivers and treatment responsiveness, with principal clinical differences driven by immunoglobulin isotype. IgA LPL emerged as a higher-risk subgroup, with more disease-related complications and inferior survival after treatment initiation. BTKi- and BR-based therapies provided superior disease control over R and Cy, with BTKi outcomes equivalent to matched WM patients. These findings provide the first evidence base for treatment selection in non-IgM LPL and support extending WM-directed therapies and clinical trials to this historically excluded population.

 

Alberto Guijosa, MD: No relevant conflicts of interest to declare.